Tag Archives: congress

Anti-cancer drug benefits women with breast cancer who have failed previous treatments

In a late-breaking presentation to the 2013 European Cancer Congress (ECC2013) [1] today, Professor Hans Wildiers will say: "This study shows that even in heavily pre-treated women, 75% of whom had cancer that has spread to the internal organs, T-DM1 nearly doubles progression-free survival — the length of time before disease progression or death, whichever occurs first — compared to standard therapy, and with a more favourable safety profile. …

Young patients with metastatic colorectal cancer at higher risk

That’s according to research presented to the 2013 European Cancer Congress in Amsterdam. The team of scientists is led by an investigator at University of Colorado Cancer Center. An analysis of 20,034 patients in 24 phase III clinical trials showed that the youngest and oldest patients had the highest risk of disease progression and death, compared to middle-aged patients…

First randomized trial of targeted cancer medicine in all tumor types

Dr Christophe Le Tourneau, Head of the Phase I Programme at the Institut Curie, Paris, France, will tell the congress that the SHIVA trial is the first randomised trial to look at patient outcomes after treatments were chosen according to the individual molecular profiles of each person’s tumour. It is also the first trial to do this for all tumour types. About 40% of all those taking part in the trial have molecular abnormalities that can be targeted by existing drugs, he will say…

Bone growth factor may increase benign tumors but not malignant cancer

Other papers in the September Neurosurgery report on a stent-assisted approach for difficult-to-treat brain aneurysms and a new software program to help in identifying and protecting critical areas during brain tumor surgery. BMP Linked to Increased Risk of Benign Tumors Dr. Nandan Lad of Duke University Medical Center and colleagues analyzed the risk of cancers and benign tumors in nearly 4,700 patients receiving BMP as part of spinal fusion surgery. …

Statins reduce cardiovascular events in coronary artery disease patients with very low LDL cholesterol levels

Dr Nakano said: "Many randomised clinical trials, such as Treating to New Targets (TNT) and PROVE IT-TIMI, have shown that aggressive cholesterol lowering with statins improves clinical outcomes in patients with CAD and high LDL-C levels.1,2 But until now it was not known whether aggressive lipid lowering with statins would also benefit CAD patients with very low LDL-C levels." The current study used the Ibaraki Cardiovascular Assessment Study (ICAS), a registry of 2,238 patients from 12 hospitals in the Ibaraki region of Japan, who between 0 and 1 month underwent percutaneous coronary interventions. Based on serum LDL-C levels at initial presentation participants were classified into three groups: very low (<70 mg/dl, n=214); low (71-100 mg/dl, n=669); and high (>101 mg/dl, n= 1,355). Decisions of whether to prescribe statins or not, as well as the type and dose, were left to the discretion of treating physicians…

Adding chemotherapy to surgery improves survival in advanced gastric cancer, study confirms

At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-year follow-up from the phase III CLASSIC trial, which added combination chemotherapy to a standard surgical procedure called D2 gastrectomy. The chemotherapy regimen studied in the trial is called XELOX, which is a combination of the drugs capecitabine and oxaliplatin. …

Immune-boosting colorectal cancer drug shows promise

The findings confirm the biological action of the drug called MGN1703 and suggest it may be possible to identify which gastrointestinal cancer patients will benefit most from the treatment, reported Prof Hans-Joachim Schmoll from Martin Luther University, Halle, Germany. MGN1703 is a small DNA molecule recognised by a receptor –called toll-like receptor 9– that is expressed in certain immune system cells. The drug is designed to broadly activate all components of the innate immune system to stimulate the destruction of cancer cells…

Venezuela considers prohibiting bottle feeding for infants

Venezuela's Congress will discuss legislation this week that would prohibit bottle feeding of infants to try to encourage breast feeding and reduce the use of baby formula, said a lawmaker of the ruling Socialist Party. Legislator Odalis Monzon said the proposal would “prohibit all types of baby bottles” as a way to improve children's health. “We want to increase the love (between mother and child) because this has been lost as a result of these transnational companies selling formula,” Monzon said on state television on Thursday. She said the Law for the Promotion and Support for Breast-Feeding, passed in 2007, did not establish any sanctions for using formula. However, she did not say what the sanctions might be if the proposed change to prohibit bottle feeding is passed by Congress, where the Socialist Party has a majority. Monzon said, however, that exceptions would be allowed, such as in the case of the death of a mother, or for women with limited breast milk production, as determined by the health ministry. She did not respond to phone calls seeking details, including how long babies would be breast-fed. Such legislation would likely raise the ire of opposition sympathizers who say the government of the late President Hugo Chavez excessively extended the reach of the state into the lives of private citizens. “People are free to feed their children as they see fit,” said Ingrid Rivero, a 27-year-old mother in Caracas. “My daughter stopped breast feeding after seven months. What can I do?